UTHR analyst estimates

United Therapeutics (UTHR) analyst ratings, the average price target and its range, and every firm's latest call.

UTHR analyst ratings and price targets

DateFirmCallTarget
Oct 26, 2026Cantor FitzgeraldUnited Therapeutics price target raised to $850 from $700 at Cantor Fitzgerald$850.00
Oct 22, 2026RBC CapitalUnited Therapeutics price target lowered to $697 from $708 at RBC Capital$697.00
Oct 20, 2026Raymond JamesUnited Therapeutics price target raised to $717 from $685 at Raymond James$717.00
Oct 19, 2026UBSUnited Therapeutics price target raised to $725 from $685 at Leerink$725.00
Oct 15, 2026Goldman SachsUnited Therapeutics price target raised to $368 from $321 at Goldman Sachs$368.00
Oct 14, 2026JefferiesUnited Therapeutics Corp. (UTHR) PT Raised to $728 at Jefferies$728.00
Oct 8, 2026RBC CapitalUnited Therapeutics price target raised to $708 from $677 at RBC Capital$708.00
Oct 1, 2026BTIGUnited Therapeutics upgraded to Buy from Neutral at BTIG$728.00
Sep 24, 2026Goldman SachsGoldman Sachs Starts United Therapeutics Corp. (UTHR) at Sell$321.00
Aug 6, 2026Morgan StanleyUnited Therapeutics price target lowered to $515 from $516 at Morgan Stanley$515.00
May 7, 2026Wells FargoUnited Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo$738.00
May 7, 2026Wells FargoUnited Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo$735.00
May 7, 2026Morgan StanleyUnited Therapeutics price target lowered to $516 from $519 at Morgan Stanley$516.00
Apr 10, 2026Raymond JamesUnited Therapeutics initiated with an Outperform at Raymond James$700.00
Apr 10, 2026Morgan StanleyUnited Therapeutics price target raised to $519 from $471 at Morgan Stanley$519.00

Updated 2026-11-02 23:58 UTC